BrainXell Therapeutics News
SAN DIEGO, May 29,2026 — BrainXell Therapeutics Global Inc, a biotechnology company translating advanced cellular sciences into autologous iPSC-derived therapies to treat devastating neurological diseases, today announced its formation, leadership team, pipeline focus and lead development program in Parkinson’s disease(PD).
BrainXell Therapeutics separated from its legacy company, BrainXell,Inc., in January 2026.
Katherine Vega Stultz, president and CEO of BrainXell Therapeutics, is a veteran biotech executive with more than two decades of experience advancing therapeutics across modalities and diseases. She brings decades of leadership in strategy, clinical development and commercialization, building high-performing teams and delivering therapies from bench to bedside.
“Although BrainXell Therapeutics itself is only just emerging, we bring a decade of experience in world-class cellular science and neurology to our pipeline,” said Ms. Stultz. “Our goal is to transform scientific possibility into practical, disease-modifying therapies that could help patients with devastating neurodegenerative diseases, like Parkinson’s disease, reclaim their lives—and we believe we’re on the right track to do just that.”
BrainXell Therapeutics is supported by Founder and Advising CSO Dr. Su-Chun Zhang, MD, PhD, a global pioneer in stem cell neuroscience and founder of BrainXell, Inc. Dr. Zhang’s research laid the scientific foundation for BrainXell Therapeutics’ proprietary iPSC technology that enables the generation of high-purity, functionally mature central nervous system (CNS) cells for drug discovery.
“I am pleased to establish BrainXell Therapeutics and see it translate my work on iPSC-derived CNS cells into therapeutics for patients—something I have aspired to since I first founded BrainXell, Inc.,” said Dr. Zhang. “We intentionally chose technologies and targets that we believed gave us the best potential for long-term success in making a tangible difference in patients’ lives. BrainXell Therapeutics has inherited the positive results of those early choices, and I have no doubt the team will carry this vital work forward with the same intentionality.”
BrainXell Therapeutics is applying its proprietary technology to the development of autologous iPSC-derived cell therapies for devastating CNS diseases, including Parkinson’s disease (PD), for which there are currently no disease-modifying therapies available in the US. The technology uses proprietary mRNA reprogramming and a unique fresh spheroid formulation to yield the best possible cell product for transplant in terms of consistency, quality, viability and engraftment ability.
Its lead program, BXT-110, an autologous iPSC-derived midbrain dopaminergic progenitor (mDAP) cell therapy has completed in vivo studies and is prepared for IND submission in 2026.
BrainXell Therapeutics also has an autologous iPSC-derived cell therapy in discovery to treat spinal cord injury (SCI) and an earlier pipeline product for stroke expanding the potential to neuro injury.
BrainXell Therapeutics is a biotechnology company that is translating advanced cellular science into autologous iPSC-derived therapies designed to regenerate the human central nervous system (CNS) after disease or injury. The company puts a decade of iPSC and neuroscience experience gained at its legacy company, BrainXell, Inc., into pipeline programs for devastating neurological diseases, including Parkinson’s disease (PD). BrainXell Therapeutics’ technology is rooted in the expertise and innovation of its advising CSO and Founder, Dr. Su-Chun Zhang, MD, PhD, a global pioneer in stem cell neuroscience. For more information, visit www.brainxelltx.com.
